Evidence map›Paper›PMID 18663368›Full record

ArticleMolecular psychiatry2010

Soluble amyloid precursor proteins in the cerebrospinal fluid as novel potential biomarkers of Alzheimer's disease: a multicenter study.

P Lewczuk, H Kamrowski-Kruck, O Peters, I Heuser, F Jessen, J Popp, K Bürger, H Hampel, L Frölich, S Wolf and 17 more

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in Molecular psychiatry, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 73 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
73citing papers in PubMed, 1 pooled it
7.1field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

73 citing papers in PubMed, 1 synthesis or guideline pooled it, 160 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Altered concentrations of amyloid precursor protein metabolites in the cerebrospinal fluid of patients with bipolar disorder.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2013
    Trial
  5. Trial
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Review
  17. Biochemical Markers in Alzheimer's Disease.International journal of molecular sciences · 2020
    Review
  18. Article
  19. Review
  20. Review

13 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors at 16 institutions in 2 countries.

P LewczukDepartment of Psychiatry and Psychotherapy, University of Erlangen-Nuremberg, Erlangen, Germany.
H Kamrowski-Kruck
O Peters
I Heuser
F Jessen
J Popp
K Bürger
H Hampel
L Frölich
S Wolf
B Prinz
H Jahn
Ch Luckhaus
R Perneczky
M Hüll
J Schröder
H Kessler
J Pantel
H-J Gertz
H-W Klafki
H Kölsch
U Reulbach
H Esselmann
J M Maler
M Bibl
J Kornhuber
J Wiltfang
Friedrich-Alexander-Universität Erlangen-Nürnberg · DEUniversity of Bonn · DEUniversity of Göttingen · DECharité - Universitätsmedizin Berlin · DECentral Institute of Mental Health · DEGoethe University Frankfurt · DEHeidelberg University · DEHeinrich Heine University Düsseldorf · DELeipzig University · DELudwig-Maximilians-Universität München · DESaarland University · DETechnical University of Munich · DEUniversität Hamburg · DEUniversity College Dublin · IEUniversity of Duisburg-Essen · DEUniversity of Freiburg · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In this report, we present the results of a multicenter study to test analytic and diagnostic performance of soluble forms of amyloid precursor proteins alpha and beta (sAPP alpha and sAPP beta) in the cerebrospinal fluid (CSF) of patients with different forms of dementing conditions. CSF samples were collected from 188 patients with early dementia (mini-mental state examination >or=20 in majority of cases) and mild cognitive impairment (MCI) in 12 gerontopsychiatric centers, and the clinical diagnoses were supported by neurochemical dementia diagnostic (NDD) tools: CSF amyloid beta peptides, Tau and phospho-Tau. sAPP alpha and sAPP beta were measured with multiplexing method based on electrochemiluminescence. sAPP alpha and sAPP beta CSF concentrations correlated with each other with very high correlation ratio (R=0.96, P<0.001). We observed highly significantly increased sAPP alpha and sAPP beta CSF concentrations in patients with NDD characteristic for Alzheimer's disease (AD) compared to those with NDD negative results. sAPP alpha and sAPP beta highly significantly separated patients with AD, whose diagnosis was supported by NDD findings (sAPP alpha: cutoff, 117.4 ng ml(-1), sensitivity, 68%, specificity, 85%, P<0.001; sAPP beta: cutoff, 181.8 ng ml(-1), sensitivity, 75%, specificity, 85%, P<0.001), from the patients clinically assessed as having other dementias and supported by NDD untypical for AD. We conclude sAPP alpha and sAPP beta might be regarded as novel promising biomarkers supporting the clinical diagnosis of AD.

Indexed as

AgedAged, 80 and overAlzheimer DiseaseAmyloid beta-PeptidesAmyloid beta-Protein PrecursorBiomarkersCognition DisordersDementiaFemaleGermanyHumansMaleMiddle AgedPsychiatric Status Rating ScalesSensitivity and SpecificityStatistics as TopicAmyloid beta-PeptidesAmyloid beta-Protein PrecursorBiomarkerstau Proteins

Identifiers

PMID18663368
OpenAlexW2072203507

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.